In vitro studies characterizing the effect of the splicing inhibitors resulted in increased apoptosis of CLL cells regardless of splicing factor 3B subunit 1 (SF3B1) status. The gene discussed is SF3B1; the disease is B-cell chronic lymphocytic leukemia.